U.S. starts seeking drugmakers' views in turning Trump's pricing deals into law
Source: SeekingAlpha
2026-03-20 08:38:07 ET
More on Eli Lilly, Johnson & Johnson, etc.
- Roche Vs. Eli Lilly: Nvidia Deals, Obesity Battles Stoke Rivalry (I'd Buy Both)
- Novo Nordisk: The Illusion Of Cheap
- Novo Nordisk - Enough Is Enough: 5 Reasons It's Time To Sell (Rating Downgrade)
- Eli Lilly, Biogen/ Eisai win U.K. review for use of Alzheimer’s drugs in NHS
- Lilly trades flat as adverse events overshadow trial win for next-gen obesity drug
Read the full article on Seeking Alpha
For further details see:
U.S. starts seeking drugmakers’ views in turning Trump's pricing deals into law
Roche Holding Ltd ADR
NASDAQ: RHHBY
RHHBY Trading
2.53% G/L:
$49.349 Last:
380,642 Volume:
$48.94 Open:
RHHBY Latest News
March 24, 2026 02:00:00 am
Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets
RHHBY Stock Data
$361,973,933,704
6,306,832,002
N/A
43
N/A
Pharmaceuticals
Healthcare
CH
Basel Switzerland
